Accéder au contenu
Merck

Oncogenic ERRB2 signals through the AP-1 transcription factor to control mesenchymal-like properties of oesophageal adenocarcinoma.

NAR cancer (2023-01-26)
Samuel Ogden, Ibrahim Ahmed, Shen-Hsi Yang, Paul Fullwood, Chiara Francavilla, Andrew D Sharrocks
RÉSUMÉ

Oesophageal adenocarcinoma (OAC) is a deadly disease with poor survival statistics and few targeted therapies available. One of the most common molecular aberrations in OAC is amplification or activation of the gene encoding the receptor tyrosine kinase ERBB2, and ERBB2 is targeted in the clinic for this subset of patients. However, the downstream consequences of these ERBB2 activating events are not well understood. Here we used a combination of phosphoproteomics, open chromatin profiling and transcriptome analysis on cell line models and patient-derived datasets to interrogate the molecular pathways operating downstream from ERBB2. Integrated analysis of these data sets converge on a model where dysregulated ERBB2 signalling is mediated at the transcriptional level by the transcription factor AP-1. AP-1 in turn controls cell behaviour by acting on cohorts of genes that regulate cell migration and adhesion, features often associated with EMT. Our study therefore provides a valuable resource for the cancer cell signalling community and reveals novel molecular determinants underlying the dysregulated behaviour of OAC cells.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Trypsine de qualité séquençage, modifiée, from bovine pancreas
Sigma-Aldrich
Anticorps monoclonal anti-α-tubuline antibody produced in mouse, clone DM1A, ascites fluid
Sigma-Aldrich
Sérum de veau fœtal, USA origin, Dialyzed by ultrafiltration against 0.15 M NaCl, sterile-filtered, suitable for cell culture